Fast track — ArticlesAxitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Introduction
The prognosis for patients with advanced pancreatic adenocarcinoma is poor, and gemcitabine, the standard of care, offers only slight benefit.1, 2 Despite extensive research, combination regimens with gemcitabine and cytotoxic or molecularly targeted agents have not significantly improved outcomes compared with gemcitabine monotherapy.3 The addition of erlotinib to gemcitabine resulted in a significant but very small improvement in overall survival.3, 4 There is a pressing need for new treatment options for this disease.
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.5 A randomised phase 2 study6 of 103 patients with locally advanced and metastatic pancreatic adenocarcinoma showed an improvement in median overall survival (6·9 vs 5·6 months; hazard ratio [HR] 0·71, 95% CI 0·44–1·13) and a greater 1-year survival (37% vs 24%) for axitinib plus gemcitabine versus gemcitabine alone. Although not significant, the apparent increase in survival in the combination group provided the rationale for a larger phase 3 study of this regimen. We aimed to assess overall survival in patients with advanced pancreatic cancer treated with gemcitabine plus axitinib versus gemcitabine plus placebo.
Section snippets
Study design and patients
We undertook a phase 3, randomised, double-blind, global, multicentre, two-group study. Eligible patients were at least 18 years old with histologically or cytologically confirmed metastatic or locally advanced pancreatic adenocarcinoma not amenable to curative resection. Patients were required to have adequate bone marrow, hepatic, and renal function (including urine protein <2 g/24 h); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and no uncontrolled hypertension
Results
Between July 27, 2007, and Oct 31, 2008, 632 patients were randomly assigned to treatment groups (316 to each group). 305 patients in the gemcitabine plus axitinib group and 308 in the gemcitabine plus placebo group received study treatment (figure 1). The baseline characteristics of the treatment groups seemed well balanced (table 1). Most patients (226 [72%] in the gemcitabine plus axitinib and 227 [72%] in the gemcitabine plus placebo group) had metastatic disease and about half had an ECOG
Discussion
This randomised phase 3 trial clearly shows that the addition of axitinib to gemcitabine does not improve survival in patients with locally advanced or metastatic pancreatic cancer. These data also confirm the findings obtained in previous phase 3 studies of the VEGF inhibitors bevacizumab and aflibercept that inhibition of this pathway is ineffective in patients with this disease (panel).13, 14, 15
In view of the long history of promising phase 2 single-group trials that have yielded negative
References (18)
- et al.
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Lancet
(2008) - et al.
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life
Eur J Cancer
(1999) - et al.
Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis
J Stat Plan Infect
(1994) - et al.
VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer
Eur J Cancer Suppl
(2009) - et al.
Cancer statistics, 2010
CA Cancer J Clin
(2010) - et al.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
J Clin Oncol
(1997) - et al.
Lessons learned in the management of advanced pancreatic cancer
J Clin Oncol
(2007) - et al.
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
J Clin Oncol
(2007) - et al.
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
Clin Cancer Res
(2008)
Cited by (352)
Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions
2023, Biochimica et Biophysica Acta - Reviews on CancerPreoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
2023, Critical Reviews in Oncology/HematologyClinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
2024, International Journal of Molecular Sciences